Mosaic ImmunoEngineering Employees

As of December 31, 2024, Mosaic ImmunoEngineering had 8 total employees, including 3 full-time and 5 part-time employees. The number of employees did not change compared to the previous year.

Employees

Change (1Y)

n/a

Growth (1Y)

n/a

Revenue / Employee

n/a

Profits / Employee

-$137,569

Market Cap

5.40M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	8	0	-
Dec 31, 2023	8	0	-
Dec 31, 2022	8	1	14.29%
Dec 31, 2021	7	0	-
Dec 31, 2020	7	-	-

Related Stocks

Company Name	Employees
Orgenesis	77
ZIVO Bioscience	7
AccuStem Sciences	4
Bioxytran	2
Synlogic	1
Galera Therapeutics	3

Employee Rankings

Mosaic ImmunoEngineering News

2 years ago - Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. - Accesswire
3 years ago - Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101 - Accesswire
3 years ago - UPDATE: Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Platform - Accesswire
3 years ago - Mosaic ImmunoEngineering's Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company's Novel Immuno-Oncology Plat-form - Accesswire
4 years ago - Mosaic ImmunoEngineering Announces Completion of Exclusive Technology License Agreement with Case Western Reserve University - Accesswire
4 years ago - Newly Published Data Further Support Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma - Accesswire
4 years ago - Mosaic ImmunoEngineering's Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation - Accesswire
4 years ago - Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference - Accesswire

More News